Ortin Laboratories Limited (ORTINLAB.NS)
- Previous Close
19.95 - Open
20.25 - Bid 19.60 x --
- Ask 19.95 x --
- Day's Range
19.60 - 20.25 - 52 Week Range
16.20 - 30.35 - Volume
336 - Avg. Volume
36,671 - Market Cap (intraday)
159.375M - Beta (5Y Monthly) 1.27
- PE Ratio (TTM)
-- - EPS (TTM)
-5.15 - Earnings Date May 27, 2024 - May 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Ortin Laboratories Limited engages in the manufacture and trading of pharmaceuticals, drugs, and intermediates in India. The company offers various pharmaceutical formulations of tablets, capsules, syrups, and dry powders. It provides formulations, such as anti-diabetics, anti allergics, sedatives and tranquilisers, anti helmenthetics, analgesics and antipyretics, anti-biotics-quinolones, anti-biotic-pencillins, antifungal, cephalosporins, and macrolides; and anti-anginal and cardio vascular, and antifungal products. Its formulations also include chemo therapeutics, antacids and anti ulcerants, anti spasmodics, calcium and iron preparations, anti-arthritic drugs, protein supplements, enzymes, and vitamins, as well as psychiatry, appetizer, gynaec, and anti-retroviral products. In addition, the company offers active pharmaceutical ingredient (API) intermediates, including anti retro viral, anti-diabetics, analgesics and antipyretics, anti-biotics, antifungal, antacids and anti ulcerants, and anti malarials; and manufactures fine chemicals, and grignard and alkali metal products. Further, the company provides services in the areas of process development, process and product characterization, analytical research and development, and assay development; and diagnostic services comprising development of rapid flow kits, assays, and reagents. Additionally, it undertakes long-term contracts for manufacturing intermediates and developing new APIs; and operates as a merchant exporter of pharmaceutical finished formulations. Ortin Laboratories Limited was incorporated in 1986 and is headquartered in Hyderabad, India.
www.ortinlabsindia.com24
Full Time Employees
March 31
Fiscal Year Ends
Sector
Related News
Performance Overview: ORTINLAB.NS
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ORTINLAB.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ORTINLAB.NS
Valuation Measures
Market Cap
162.79M
Enterprise Value
219.62M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.86
Price/Book (mrq)
1.66
Enterprise Value/Revenue
6.42
Enterprise Value/EBITDA
-6.42
Financial Highlights
Profitability and Income Statement
Profit Margin
-119.76%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
34.23M
Net Income Avi to Common (ttm)
-41M
Diluted EPS (ttm)
-5.15
Balance Sheet and Cash Flow
Total Cash (mrq)
3.17M
Total Debt/Equity (mrq)
61.58%
Levered Free Cash Flow (ttm)
--
Company Insights: ORTINLAB.NS
ORTINLAB.NS does not have Company Insights